Keywords: idenix, licenses, valopicitabine, novartis, 70m, deal, pharmaceuticals
Idenix licenses valopicitabine to Novartis in $70M deal
Article | 03 April 2006
Idenix Pharmaceuticals, a USA-based biopharmaceutical company focused on infectious diseases, says that Novartis has exercised its option to license valopicitabine ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
